246 related articles for article (PubMed ID: 34384938)
1. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges.
Liu C; Shi M; Zhu M; Chu F; Jin T; Zhu J
Autoimmun Rev; 2022 Jan; 21(1):102921. PubMed ID: 34384938
[TBL] [Abstract][Full Text] [Related]
2. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
3. Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD.
Shi M; Chu F; Jin T; Zhu J
CNS Neurosci Ther; 2022 Jul; 28(7):981-991. PubMed ID: 35426485
[TBL] [Abstract][Full Text] [Related]
4. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of neuromyelitis optica spectrum disorders - An update.
Bruscolini A; Sacchetti M; La Cava M; Gharbiya M; Ralli M; Lambiase A; De Virgilio A; Greco A
Autoimmun Rev; 2018 Mar; 17(3):195-200. PubMed ID: 29339316
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
Alves Do Rego C; Collongues N
Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies.
Mejdoub S; Feki S; Dammak M; Farhat N; Hdiji O; Boukthir S; Hachicha H; Mhiri C; Masmoudi H
Rev Neurol (Paris); 2020 May; 176(4):261-267. PubMed ID: 31668529
[TBL] [Abstract][Full Text] [Related]
8. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.
Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW
Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
10. Saudi consensus recommendations on the management of Neuromyelitis Optica Spectrum Disorders (NMOSD).
Shosha E; Aljarallah SA; Al Fugham N; Al-Jedai AH; Al Luqmani MM; Al Malik YM; Al Mudaiheem HY; Al Otaibi HS; Al Thekair FY; Al Thubaiti IA; Al Yafeai RH; Ben Slimane NS; Bunyan RF; Cupler EJ; Mubarki SM; Saeedi JA; Al Jumah MA
Mult Scler Relat Disord; 2022 Oct; 66():104062. PubMed ID: 35908449
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population].
Simaniv TO; Kochergin IA; Zakharova MN; Korobko DS; Zaslavskii LG; Zelenova OV; Abramov SI
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):96-103. PubMed ID: 34460164
[TBL] [Abstract][Full Text] [Related]
12. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
13. Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay.
Pandit L; Malli C; D'Cunha A; Sudhir A
J Neuroimmunol; 2021 Nov; 360():577706. PubMed ID: 34507014
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis Spectrum Disorders.
Weinshenker BG; Wingerchuk DM
Mayo Clin Proc; 2017 Apr; 92(4):663-679. PubMed ID: 28385199
[TBL] [Abstract][Full Text] [Related]
15. Radiculopathy in neuromyelitis optica. How does anti-AQP4 Ab involve PNS?
Kim S; Park J; Kwon BS; Park JW; Lee HJ; Choi JH; Nam K
Mult Scler Relat Disord; 2017 Nov; 18():77-81. PubMed ID: 29141825
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Neuromyelitis Optica Spectrum Disorders.
Chan KH; Lee CY
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445343
[TBL] [Abstract][Full Text] [Related]
17. Status of the neuromyelitis optica spectrum disorder in Latin America.
Rivera VM; Hamuy F; Rivas V; Gracia F; Rojas JI; Bichuetti DB; Villa AM; Marques VD; Soto A; Bertado B; Frenk IT; Galleguillos L; Quiñones J; Ramirez DA; Caparó-Zamalloa C; Ciampi E; Lana-Peixoto MA; Rodríguez E; Zarco L; Sinay V; Armas E; Becker J; Benzadón A; Lopez E; Carnero Contentti E; Correa-Diaz EP; Diaz A; Fleitas CV; Playas G; Molina O; Rojas E; Sato D; Soto I; Céspedes JV; Correale J; Barboza A; Monterrey P; Candelario A; Tavolini DR; Parajeles A; Pujol BS; Diaz de la Fe A; Alonso R; Bolaña C; Guzman MK; Carrá A; Gamarra OG; Raggio JV; Rodriguez LC; Ramirez NE; Ordoñez L; Skromne E; Portillo LL; Canabal AP; Weiser R; Sirias V; Calderón RF; Cornejo EA; Hernández M; Quiroz JCD; Garcia LA; Cedeño CO; Martínez J; Abad-Herrera P
Mult Scler Relat Disord; 2021 Aug; 53():103083. PubMed ID: 34171682
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis.
Deng S; Lei Q; Lu W
Front Immunol; 2021; 12():800666. PubMed ID: 35069584
[TBL] [Abstract][Full Text] [Related]
19. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review.
Siriratnam P; Huda S; Butzkueven H; van der Walt A; Jokubaitis V; Monif M
Autoimmun Rev; 2024 Feb; 23(2):103499. PubMed ID: 38061621
[TBL] [Abstract][Full Text] [Related]
20. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
